# Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

> **NCT01816035** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 13 (actual)

## Conditions studied

- HER2/Neu Positive
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT01816035
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-12
- **Final completion:** 2017-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01816035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01816035, "Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01816035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*